Pregnant women with metabolic dysfunction-associated steatotic liver disease (MASLD) have an increased risk of giving birth prematurely and the risk increase cannot be explained by obesity, according ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Chances are, you haven’t heard of metabolic dysfunction–associated steatohepatitis (MASH)—but you’ve almost definitely heard ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

HealthDay News — For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% ...

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

The reserarchers found that a weekly dose of semaglutide was effective at treating Metabolic Dysfunction-Associated ...